JUL 26, 2018
Macular Disease, Retina/Vitreous
In this interview from ASRS 2018, Dr. Anne Fung discusses the topline results from a phase 2 trial for the port delivery system (PDS) for ranibizumab. The refillable implant is surgically implanted into the eye, and is designed to continuously release a special formulation of ranibizumab over time. The study enrolled 243 patients who were randomized to 1 of 3 PDS doses (10, 40 or 100 mg/ml) or monthly intravitreal ranibizumab injections (0.5 mg). For the 100 mg/ml PDS dose, more than 80% of patients were able to go for 6 months or longer until the first refill. Dr. Fung is hopeful that the device will reduce the high treatment burden associated with monthly intravitreal injections for patients with wet AMD. A phase 3 trial is expected to commence later this year.
Relevant Financial Disclosures: Dr. Fung is an employee of Genentech.